Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by fatty lesions and fat accumulation in hepatic parenchymal cells, which is in the absence of excessive alcohol consumption or definite liver damage factors. The exact pathogenesis of NAFLD is not fully unders...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2023-09, Vol.954, p.175834-175834, Article 175834
Hauptverfasser: Yuan, Shuo, Zhang, Hua-Min, Li, Jia-Xin, Li, You, Wang, Qi, Kong, Guang-Yao, Li, Ao-Han, Nan, Ji-Xing, Chen, Ying-Qing, Zhang, Qing-Gao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 175834
container_issue
container_start_page 175834
container_title European journal of pharmacology
container_volume 954
creator Yuan, Shuo
Zhang, Hua-Min
Li, Jia-Xin
Li, You
Wang, Qi
Kong, Guang-Yao
Li, Ao-Han
Nan, Ji-Xing
Chen, Ying-Qing
Zhang, Qing-Gao
description Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by fatty lesions and fat accumulation in hepatic parenchymal cells, which is in the absence of excessive alcohol consumption or definite liver damage factors. The exact pathogenesis of NAFLD is not fully understood, but it is now recognized that oxidative stress, insulin resistance, and inflammation are essential mechanisms involved in the development and treatment of NAFLD. NAFLD therapy aims to stop, delay or reverse disease progressions, as well as improve the quality of life and clinical outcomes of patients with NAFLD. Gasotransmitters are produced by enzymatic reactions, regulated through metabolic pathways in vivo, which can freely penetrate cell membranes with specific physiological functions and targets. Three gasotransmitters, nitric oxide, carbon monoxide, and hydrogen sulfide have been discovered. Gasotransmitters exhibit the effects of anti-inflammatory, anti-oxidant, vasodilatory, and cardioprotective agents. Gasotransmitters and their donors can be used as new gas-derived drugs and provide new approaches to the clinical treatment of NAFLD. Gasotransmitters can modulate inflammation, oxidative stress, and numerous signaling pathways to protect against NAFLD. In this paper, we mainly review the status of gasotransmitters research on NAFLD. It provides clinical applications for the future use of exogenous and endogenous gasotransmitters for the treatment of NAFLD. [Display omitted]
doi_str_mv 10.1016/j.ejphar.2023.175834
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2827263813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S001429992300345X</els_id><sourcerecordid>2827263813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-3fdb3b25dc27680f437ddece12bbe40feafd480fc2c8a624be998158d531d8623</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMotlb_gUiWbqbmMY-MC0GKVqEgiK5DJrljM0wnNckU-u-dOurS1b0czrmH-yF0ScmcEprfNHNotmvl54wwPqdFJnh6hKZUFGVCCsqO0ZQQmiasLMsJOguhIYRkJctO0YQXfJALMkWvSxVc9KoLGxsj-IBthzvXJarVbu1aq3GtYtzj1u7AY2MDqAC3uOlDxHENONotdvX3ajVU4D_O0Umt2gAXP3OG3h8f3hZPyepl-by4XyWa5ywmvDYVr1hmNCtyQeqUF8aABsqqClJSg6pNOuiaaaFyllZQloJmwmScGpEzPkPX492td589hCg3NmhoW9WB64NkghUs54LywZqOVu1dCB5qufV2o_xeUiIPNGUjR5ryQFOONIfY1U9DX23A_IV-8Q2Gu9EAw587C14GbaHTYKwHHaVx9v-GL2sViIc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2827263813</pqid></control><display><type>article</type><title>Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Yuan, Shuo ; Zhang, Hua-Min ; Li, Jia-Xin ; Li, You ; Wang, Qi ; Kong, Guang-Yao ; Li, Ao-Han ; Nan, Ji-Xing ; Chen, Ying-Qing ; Zhang, Qing-Gao</creator><creatorcontrib>Yuan, Shuo ; Zhang, Hua-Min ; Li, Jia-Xin ; Li, You ; Wang, Qi ; Kong, Guang-Yao ; Li, Ao-Han ; Nan, Ji-Xing ; Chen, Ying-Qing ; Zhang, Qing-Gao</creatorcontrib><description>Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by fatty lesions and fat accumulation in hepatic parenchymal cells, which is in the absence of excessive alcohol consumption or definite liver damage factors. The exact pathogenesis of NAFLD is not fully understood, but it is now recognized that oxidative stress, insulin resistance, and inflammation are essential mechanisms involved in the development and treatment of NAFLD. NAFLD therapy aims to stop, delay or reverse disease progressions, as well as improve the quality of life and clinical outcomes of patients with NAFLD. Gasotransmitters are produced by enzymatic reactions, regulated through metabolic pathways in vivo, which can freely penetrate cell membranes with specific physiological functions and targets. Three gasotransmitters, nitric oxide, carbon monoxide, and hydrogen sulfide have been discovered. Gasotransmitters exhibit the effects of anti-inflammatory, anti-oxidant, vasodilatory, and cardioprotective agents. Gasotransmitters and their donors can be used as new gas-derived drugs and provide new approaches to the clinical treatment of NAFLD. Gasotransmitters can modulate inflammation, oxidative stress, and numerous signaling pathways to protect against NAFLD. In this paper, we mainly review the status of gasotransmitters research on NAFLD. It provides clinical applications for the future use of exogenous and endogenous gasotransmitters for the treatment of NAFLD. [Display omitted]</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2023.175834</identifier><identifier>PMID: 37329970</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Carbon monoxide ; Gasotransmitters ; Hydrogen sulfide ; Nitric oxide ; Non-alcoholic fatty liver disease</subject><ispartof>European journal of pharmacology, 2023-09, Vol.954, p.175834-175834, Article 175834</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-3fdb3b25dc27680f437ddece12bbe40feafd480fc2c8a624be998158d531d8623</citedby><cites>FETCH-LOGICAL-c362t-3fdb3b25dc27680f437ddece12bbe40feafd480fc2c8a624be998158d531d8623</cites><orcidid>0000-0002-7140-3822</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2023.175834$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37329970$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, Shuo</creatorcontrib><creatorcontrib>Zhang, Hua-Min</creatorcontrib><creatorcontrib>Li, Jia-Xin</creatorcontrib><creatorcontrib>Li, You</creatorcontrib><creatorcontrib>Wang, Qi</creatorcontrib><creatorcontrib>Kong, Guang-Yao</creatorcontrib><creatorcontrib>Li, Ao-Han</creatorcontrib><creatorcontrib>Nan, Ji-Xing</creatorcontrib><creatorcontrib>Chen, Ying-Qing</creatorcontrib><creatorcontrib>Zhang, Qing-Gao</creatorcontrib><title>Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by fatty lesions and fat accumulation in hepatic parenchymal cells, which is in the absence of excessive alcohol consumption or definite liver damage factors. The exact pathogenesis of NAFLD is not fully understood, but it is now recognized that oxidative stress, insulin resistance, and inflammation are essential mechanisms involved in the development and treatment of NAFLD. NAFLD therapy aims to stop, delay or reverse disease progressions, as well as improve the quality of life and clinical outcomes of patients with NAFLD. Gasotransmitters are produced by enzymatic reactions, regulated through metabolic pathways in vivo, which can freely penetrate cell membranes with specific physiological functions and targets. Three gasotransmitters, nitric oxide, carbon monoxide, and hydrogen sulfide have been discovered. Gasotransmitters exhibit the effects of anti-inflammatory, anti-oxidant, vasodilatory, and cardioprotective agents. Gasotransmitters and their donors can be used as new gas-derived drugs and provide new approaches to the clinical treatment of NAFLD. Gasotransmitters can modulate inflammation, oxidative stress, and numerous signaling pathways to protect against NAFLD. In this paper, we mainly review the status of gasotransmitters research on NAFLD. It provides clinical applications for the future use of exogenous and endogenous gasotransmitters for the treatment of NAFLD. [Display omitted]</description><subject>Carbon monoxide</subject><subject>Gasotransmitters</subject><subject>Hydrogen sulfide</subject><subject>Nitric oxide</subject><subject>Non-alcoholic fatty liver disease</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLAzEUhYMotlb_gUiWbqbmMY-MC0GKVqEgiK5DJrljM0wnNckU-u-dOurS1b0czrmH-yF0ScmcEprfNHNotmvl54wwPqdFJnh6hKZUFGVCCsqO0ZQQmiasLMsJOguhIYRkJctO0YQXfJALMkWvSxVc9KoLGxsj-IBthzvXJarVbu1aq3GtYtzj1u7AY2MDqAC3uOlDxHENONotdvX3ajVU4D_O0Umt2gAXP3OG3h8f3hZPyepl-by4XyWa5ywmvDYVr1hmNCtyQeqUF8aABsqqClJSg6pNOuiaaaFyllZQloJmwmScGpEzPkPX492td589hCg3NmhoW9WB64NkghUs54LywZqOVu1dCB5qufV2o_xeUiIPNGUjR5ryQFOONIfY1U9DX23A_IV-8Q2Gu9EAw587C14GbaHTYKwHHaVx9v-GL2sViIc</recordid><startdate>20230905</startdate><enddate>20230905</enddate><creator>Yuan, Shuo</creator><creator>Zhang, Hua-Min</creator><creator>Li, Jia-Xin</creator><creator>Li, You</creator><creator>Wang, Qi</creator><creator>Kong, Guang-Yao</creator><creator>Li, Ao-Han</creator><creator>Nan, Ji-Xing</creator><creator>Chen, Ying-Qing</creator><creator>Zhang, Qing-Gao</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7140-3822</orcidid></search><sort><creationdate>20230905</creationdate><title>Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg</title><author>Yuan, Shuo ; Zhang, Hua-Min ; Li, Jia-Xin ; Li, You ; Wang, Qi ; Kong, Guang-Yao ; Li, Ao-Han ; Nan, Ji-Xing ; Chen, Ying-Qing ; Zhang, Qing-Gao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-3fdb3b25dc27680f437ddece12bbe40feafd480fc2c8a624be998158d531d8623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Carbon monoxide</topic><topic>Gasotransmitters</topic><topic>Hydrogen sulfide</topic><topic>Nitric oxide</topic><topic>Non-alcoholic fatty liver disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, Shuo</creatorcontrib><creatorcontrib>Zhang, Hua-Min</creatorcontrib><creatorcontrib>Li, Jia-Xin</creatorcontrib><creatorcontrib>Li, You</creatorcontrib><creatorcontrib>Wang, Qi</creatorcontrib><creatorcontrib>Kong, Guang-Yao</creatorcontrib><creatorcontrib>Li, Ao-Han</creatorcontrib><creatorcontrib>Nan, Ji-Xing</creatorcontrib><creatorcontrib>Chen, Ying-Qing</creatorcontrib><creatorcontrib>Zhang, Qing-Gao</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, Shuo</au><au>Zhang, Hua-Min</au><au>Li, Jia-Xin</au><au>Li, You</au><au>Wang, Qi</au><au>Kong, Guang-Yao</au><au>Li, Ao-Han</au><au>Nan, Ji-Xing</au><au>Chen, Ying-Qing</au><au>Zhang, Qing-Gao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2023-09-05</date><risdate>2023</risdate><volume>954</volume><spage>175834</spage><epage>175834</epage><pages>175834-175834</pages><artnum>175834</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by fatty lesions and fat accumulation in hepatic parenchymal cells, which is in the absence of excessive alcohol consumption or definite liver damage factors. The exact pathogenesis of NAFLD is not fully understood, but it is now recognized that oxidative stress, insulin resistance, and inflammation are essential mechanisms involved in the development and treatment of NAFLD. NAFLD therapy aims to stop, delay or reverse disease progressions, as well as improve the quality of life and clinical outcomes of patients with NAFLD. Gasotransmitters are produced by enzymatic reactions, regulated through metabolic pathways in vivo, which can freely penetrate cell membranes with specific physiological functions and targets. Three gasotransmitters, nitric oxide, carbon monoxide, and hydrogen sulfide have been discovered. Gasotransmitters exhibit the effects of anti-inflammatory, anti-oxidant, vasodilatory, and cardioprotective agents. Gasotransmitters and their donors can be used as new gas-derived drugs and provide new approaches to the clinical treatment of NAFLD. Gasotransmitters can modulate inflammation, oxidative stress, and numerous signaling pathways to protect against NAFLD. In this paper, we mainly review the status of gasotransmitters research on NAFLD. It provides clinical applications for the future use of exogenous and endogenous gasotransmitters for the treatment of NAFLD. [Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>37329970</pmid><doi>10.1016/j.ejphar.2023.175834</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7140-3822</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2023-09, Vol.954, p.175834-175834, Article 175834
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_2827263813
source ScienceDirect Journals (5 years ago - present)
subjects Carbon monoxide
Gasotransmitters
Hydrogen sulfide
Nitric oxide
Non-alcoholic fatty liver disease
title Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A55%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gasotransmitters%20in%20non-alcoholic%20fatty%20liver%20disease:%20just%20the%20tip%20of%20the%20iceberg&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Yuan,%20Shuo&rft.date=2023-09-05&rft.volume=954&rft.spage=175834&rft.epage=175834&rft.pages=175834-175834&rft.artnum=175834&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2023.175834&rft_dat=%3Cproquest_cross%3E2827263813%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2827263813&rft_id=info:pmid/37329970&rft_els_id=S001429992300345X&rfr_iscdi=true